2Q Revenues: $58.2 million (-2%)
2Q Earnings: $4.8 million (-13%)
YTD Revenues: $114.3 million (-5%)
YTD Earnings: $6.4 million (-37%)
Comments: The drop in revenues was blamed on reduced demand for some large products, a supply chain disruption at a customer's facility, lower pricing on generic APIs, and a renegotiated contract extension for drug delivery products, resulting in lower pricing. Increased sales volume for controlled substances and generic APIs helped offset some of the drop.